- Home
- LGVN vs IMRN Comparison
LGVN vs IMRN Comparison
Compare LGVN & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- IMRN
- Stock Information
- Founded
- LGVN 2014
- IMRN 1994
- Country
- LGVN United States
- IMRN Australia
- Employees
- LGVN N/A
- IMRN N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- LGVN Health Care
- IMRN Health Care
- Exchange
- LGVN Nasdaq
- IMRN Nasdaq
- Market Cap
- LGVN 17.6M
- IMRN 14.4M
- IPO Year
- LGVN 2021
- IMRN N/A
- Fundamental
- Price
- LGVN $0.63
- IMRN $1.62
- Analyst Decision
- LGVN Strong Buy
- IMRN
- Analyst Count
- LGVN 2
- IMRN 0
- Target Price
- LGVN $6.50
- IMRN N/A
- AVG Volume (30 Days)
- LGVN 388.1K
- IMRN 388.3K
- Earning Date
- LGVN 11-04-2025
- IMRN 08-29-2025
- Dividend Yield
- LGVN N/A
- IMRN N/A
- EPS Growth
- LGVN N/A
- IMRN N/A
- EPS
- LGVN N/A
- IMRN N/A
- Revenue
- LGVN $1,437,000.00
- IMRN $4,777,422.00
- Revenue This Year
- LGVN N/A
- IMRN N/A
- Revenue Next Year
- LGVN N/A
- IMRN N/A
- P/E Ratio
- LGVN N/A
- IMRN N/A
- Revenue Growth
- LGVN N/A
- IMRN 48.63
- 52 Week Low
- LGVN $0.59
- IMRN $1.42
- 52 Week High
- LGVN $2.24
- IMRN $2.48
- Technical
- Relative Strength Index (RSI)
- LGVN 30.36
- IMRN 43.49
- Support Level
- LGVN $0.59
- IMRN $1.47
- Resistance Level
- LGVN $0.67
- IMRN $1.69
- Average True Range (ATR)
- LGVN 0.05
- IMRN 0.11
- MACD
- LGVN -0.01
- IMRN 0.01
- Stochastic Oscillator
- LGVN 16.06
- IMRN 92.59
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.